PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34910759-1 2021 Genetic variants in the OPRM1 and CYP2B6 genes, respectively coding for an opioid receptor and methadone metabolizers, have been linked to negative treatment outcomes in patients undergoing methadone maintenance treatment, with little consensus on their effect. Methadone 95-104 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 15371986-0 2004 Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Methadone 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 31-57 15371986-22 2004 In vitro experiments showed a predominant role for both CYP3A4 and CYP2B6 in liver microsomal methadone N -demethylation. Methadone 94-103 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 67-73 15371986-26 2004 Interindividual variability and drug interactions affecting intestinal transporter and hepatic CYP3A and CYP2B6 activity may alter methadone disposition. Methadone 131-140 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 105-111 14628297-5 2004 Only CYP2B6, 2C19, and 3A4 generated measurable EDDP from 1 microg/ml of racemic methadone. Methadone 81-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 5-11 14628297-7 2004 At 10 microg/ml of methadone, CYP2C9 and CYP2D6 also generated EDDP, but in at least 10-fold lower quantities than CYP2B6. Methadone 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 115-121 14628297-9 2004 In human liver microsomes with high and low CYP2B6 expression but equivalent CYP3A4 expression, high CYP2B6 expression microsomes generated twice the amount of EDDP from 10 microg/ml of methadone than low CYP2B6 expression microsomes. Methadone 186-195 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 14628297-9 2004 In human liver microsomes with high and low CYP2B6 expression but equivalent CYP3A4 expression, high CYP2B6 expression microsomes generated twice the amount of EDDP from 10 microg/ml of methadone than low CYP2B6 expression microsomes. Methadone 186-195 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 43-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 43-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-139 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 116-125 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 116-125 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-139 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 167-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 167-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-139 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 217-230 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 14628297-10 2004 When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. Methadone 217-230 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-139 14628297-11 2004 These data suggest that multiple CYPs metabolized methadone but CYP2B6 had the highest V(max)/K(m). Methadone 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 64-70 14628297-13 2004 Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics. Methadone 65-74 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 113-119 14628297-13 2004 Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics. Methadone 165-174 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 113-119 14628297-13 2004 Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics. Methadone 165-174 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 113-119 34910759-0 2021 Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. Methadone 67-76 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-32 34910759-1 2021 Genetic variants in the OPRM1 and CYP2B6 genes, respectively coding for an opioid receptor and methadone metabolizers, have been linked to negative treatment outcomes in patients undergoing methadone maintenance treatment, with little consensus on their effect. Methadone 190-199 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 34910759-2 2021 This study aims to test the associations between pre-selected SNPs of OPRM1 and CYP2B6 and outcomes of continued opioid use, relapse, and methadone dose. Methadone 138-147 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 80-86 34482033-12 2021 The CYP 2B6*4 variant decreased S-methadone CL/F by 18%. Methadone 32-43 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-11 34100292-6 2021 Results: CYP2B6 poor metabolizers (*6/*6) had >twofold lower methadone metabolism compared with normal/rapid metabolizers. Methadone 61-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 34100292-10 2021 Conclusion: We have described novel associations between CYP2B6 genetic variants and perioperative methadone metabolism, and associations with pain scores and PONV. Methadone 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 30973652-7 2019 Methadone exposure was reduced when it was coadministered with CYP2B6 inducers. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 35538637-1 2022 AIMS: Methadone metabolism and clearance are determined principally by polymorphic cytochrome P4502B6 (CYP2B6). Methadone 6-15 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-109 35538637-2 2022 Some CYP2B6 allelic variants affect methadone metabolism in vitro and disposition in vivo. Methadone 36-45 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 5-11 35538637-3 2022 We assessed methadone metabolism by CYP2B6 minor variants in vitro. Methadone 12-21 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 36-42 35538637-11 2022 CYP2B6.1 expressed with POR variants POR.28, POR.5, and P228L had lower rates of methadone metabolism than wild-type reductase. Methadone 81-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 35538637-12 2022 In vivo, methadone clinical clearance decreased linearly with the number of CYP2B6 slow metabolizer alleles, but were not different in CYP2C19 slow or rapid metabolizer phenotypes, or in carriers of the POR*28 allele. Methadone 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 76-82 35538637-13 2022 CONCLUSIONS: Several CYP2B6 and POR variants were slow metabolizers of methadone in vitro. Methadone 71-80 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 35538637-14 2022 Polymorphisms in CYP2B6, but not CYP2C19 or P450 reductase, affected methadone clearance in vivo. Methadone 69-78 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 35538637-15 2022 CYP2B6 polymorphisms 516G>T and 983T>C code for canonical loss of function variants, and should be assessed when considering genetic influences on clinical methadone disposition. Methadone 156-165 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 33599403-2 2021 Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. Methadone 110-119 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 33546554-0 2021 Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran. Methadone 66-75 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-24 33546554-3 2021 Therefore, this study designed to examine the frequency of two SNPs of the CYP2B6 gene (rs3745274 and rs3211371) in addicted cases in two methadone-responders and methadone non-responders groups. Methadone 138-147 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 75-81 33546554-3 2021 Therefore, this study designed to examine the frequency of two SNPs of the CYP2B6 gene (rs3745274 and rs3211371) in addicted cases in two methadone-responders and methadone non-responders groups. Methadone 163-172 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 75-81 33546554-7 2021 Conclusion: Based on our findings, we can conclude that rs3745274 variant of CYP2B6 gene could serve as a potential biomarker, to evaluate the prognosis of addicted people fate under treatment with methadone. Methadone 198-207 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 77-83 32302325-8 2020 We assessed hepatic fibrosis and steatosis by transient elastography and CYP2B6 alleles, principally responsible for methadone metabolism. Methadone 117-126 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 73-79 32302325-13 2020 CYP2B6 loss of function (LOF) alleles significantly affected (S)-methadone metabolism (p = 0.012). Methadone 65-74 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 32302325-17 2020 Although the principal methadone metabolizing enzyme remains controversial, our results suggest that sex, CYP2B6 genotype, and BMI should be incorporated into multivariate models to create methadone dosing algorithms. Methadone 189-198 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 106-112 35356868-5 2022 RESULTS: When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5, the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient: 0.70; 95% CI: -2.16, 3.57; P: 0.631), even among those with advanced cirrhosis (-0.50; -4.59, 3.59; 0.810). Methadone 128-137 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 35194103-1 2022 Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone). Methadone 228-237 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 6-12 34380995-8 2022 RESULTS: An effective methadone dose correlated with sex, BMI and the presence of ABCB1 2677GG (rs2032582) and CYP2B6 516GG (rs374527). Methadone 22-31 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 111-117 32841585-6 2021 In terms of metabolism biomarkers, a lower methadone requirement was related to carriers of CYP2B6 genotypes *4(G/G) and *9(T/T) among Jewish patients, CYP2B6*9 genotype (T/T) and haplotypes (TA/TG); and CYP2C19 (*2/*2,*2/*3, and *3/*3; Han Chinese). Methadone 43-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 92-98 32841585-6 2021 In terms of metabolism biomarkers, a lower methadone requirement was related to carriers of CYP2B6 genotypes *4(G/G) and *9(T/T) among Jewish patients, CYP2B6*9 genotype (T/T) and haplotypes (TA/TG); and CYP2C19 (*2/*2,*2/*3, and *3/*3; Han Chinese). Methadone 43-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 152-158 32841585-8 2021 Lower methadone levels were reported in CYP2B6 SNPs, haplotypes TTT, and AGATAA (Han Chinese), CYP2C19 genotype *1/*1 (Han Chinese), allelic carrier *1xN (Caucasian), and CYP3A4 genotype *1/*1 (Caucasian). Methadone 6-15 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 32841585-9 2021 Carriers of CYP2B6 genotype *6/*6 (Caucasian), CYP2B6 haplotypes ATGCAG and ATGCTG (Han Chinese), and CYP3A4 genotype *1/*1B (Caucasian) had predicted higher methadone plasma levels. Methadone 158-167 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 32870067-2 2020 The metabolism of methadone is complex and executed mainly by the cytochromes, CYP3A4 and CYP2B6. Methadone 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-96 32564328-5 2020 Understanding of the mechanisms of variability in methadone disposition and drug interactions has evolved over the years, with the latest evidence revealing that CYP 2B6 is the major determinant of methadone elimination and plays a key role in methadone-related drug interactions. Methadone 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 162-169 32564328-5 2020 Understanding of the mechanisms of variability in methadone disposition and drug interactions has evolved over the years, with the latest evidence revealing that CYP 2B6 is the major determinant of methadone elimination and plays a key role in methadone-related drug interactions. Methadone 198-207 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 162-169 32564328-5 2020 Understanding of the mechanisms of variability in methadone disposition and drug interactions has evolved over the years, with the latest evidence revealing that CYP 2B6 is the major determinant of methadone elimination and plays a key role in methadone-related drug interactions. Methadone 198-207 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 162-169 30973652-9 2019 In conclusion, CYP2B6 plays a prominent role in methadone metabolism, although methadone exposure is not sensitive to CYP3A perturbation. Methadone 48-57 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 30973652-10 2019 In designing methadone DDI studies, (1) measuring R- and S-methadone is more informative than measuring total methadone, and (2) CYP2B6 genotyping of subjects enrolled in methadone DDI studies should be considered. Methadone 13-22 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 129-135 30907440-0 2019 Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Methadone 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 30907440-1 2019 AIMS: Our study aimed to evaluate the impacts of the cytochrome P450 (CYP) 2B6-G516T and CYP2D6 genetic polymorphisms on pharmacokinetic and clinical parameters in patients receiving methadone maintenance treatment. Methadone 183-192 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 53-78 30907440-4 2019 RESULTS: When comparing the three CYP2B6 genotype groups, the methadone (R)- and (S)-methadone enantiomer concentrations/doses (concentrations relative to doses) were different (P = .029, P = .0019). Methadone 62-71 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 30907440-4 2019 RESULTS: When comparing the three CYP2B6 genotype groups, the methadone (R)- and (S)-methadone enantiomer concentrations/doses (concentrations relative to doses) were different (P = .029, P = .0019). Methadone 81-94 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 30907440-7 2019 CONCLUSION: The genotyping of CYP2B6 G516T could be an interesting tool to explore methadone intervariability. Methadone 83-92 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 30-36 30201214-1 2018 Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ). Methadone 184-193 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-45 30906561-8 2019 Furthermore, metabolism of common CYP2B6 probe substrates, methadone and ketamine, is not detected in the presence of brain microsomes. Methadone 59-68 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 30205091-2 2018 Methadone undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2C9, and CYP2C8. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 96-102 30205091-3 2018 In vivo, polymorphism effects on methadone systemic exposure have been noted for CYP2B6, CYP3A4, and CYP2D6. Methadone 33-42 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-87 30201214-1 2018 Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ). Methadone 184-193 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 28723731-9 2017 CONCLUSIONS: Patients homozygous for CYP2B6*6 had a >90% higher methadone C/D ratio. Methadone 67-76 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 29458047-4 2018 Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 99-105 29458047-6 2018 Several SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in increases in methadone plasma concentrations, decreased N-demethylation, and decreased methadone clearance. Methadone 81-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 29458047-6 2018 Several SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in increases in methadone plasma concentrations, decreased N-demethylation, and decreased methadone clearance. Methadone 155-164 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 29458047-7 2018 In particular, carriers of CYP2B6*6/*6 may have a greater risk for detrimental adverse effects, as methadone metabolism and clearance are diminished in these individuals. Methadone 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 29458047-8 2018 CYP2B6*4, on the other hand, has been observed to decrease plasma concentrations of methadone due to increased methadone clearance. Methadone 84-93 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 29458047-8 2018 CYP2B6*4, on the other hand, has been observed to decrease plasma concentrations of methadone due to increased methadone clearance. Methadone 111-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 29458047-9 2018 The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine. Methadone 101-110 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 69-75 29458047-9 2018 The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine. Methadone 158-167 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 69-75 28699698-3 2017 This study discovered that the estrogen-response element single nucleotide polymorphism (ERE-SNP; rs16974799, C/T) of cytochrome 2B6 gene (cyp2b6; methadone catabolic enzyme) responded differently to MMT dosing. Methadone 147-156 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 139-145 28723731-0 2017 Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. Methadone 102-111 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 19-25 28723731-2 2017 The aim of this study was to clarify the impact of the reduced function CYP2B6*6 variant allele together with variants in other candidate genes on a steady-state methadone concentration in a naturalistic setting. Methadone 162-171 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 28723731-6 2017 The estimated mean methadone C/D ratios was 17.8 nmol L mg for homozygous carriers of CYP2B6*6, which was significantly (P < 0.001) higher than noncarriers (9.2 nmol L mg). Methadone 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 86-92 28723731-10 2017 Genotyping of CYP2B6 may therefore be of value when assessing dose requirements in methadone maintenance treatment. Methadone 83-92 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 14-20 28184434-0 2017 Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities. Methadone 38-47 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 29302220-6 2017 In pharmacogenetics of opioid addictions, methadone dose may be regulated by variants in cytochrome P450 2B6 (CYP2B6), a methadone-metabolizing enzyme, and by a locus 300 kb 5" to OPRM1. Methadone 42-51 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 89-108 29302220-6 2017 In pharmacogenetics of opioid addictions, methadone dose may be regulated by variants in cytochrome P450 2B6 (CYP2B6), a methadone-metabolizing enzyme, and by a locus 300 kb 5" to OPRM1. Methadone 42-51 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 110-116 29302220-6 2017 In pharmacogenetics of opioid addictions, methadone dose may be regulated by variants in cytochrome P450 2B6 (CYP2B6), a methadone-metabolizing enzyme, and by a locus 300 kb 5" to OPRM1. Methadone 121-130 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 89-108 29302220-6 2017 In pharmacogenetics of opioid addictions, methadone dose may be regulated by variants in cytochrome P450 2B6 (CYP2B6), a methadone-metabolizing enzyme, and by a locus 300 kb 5" to OPRM1. Methadone 121-130 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 110-116 28320034-0 2017 Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers. Methadone 139-148 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 28184434-4 2017 The purpose of this study was to determine if one or more single nucleotide polymorphisms (SNPs) located within the CYP2B6 gene contributes to a poor metabolizer phenotype for methadone in these fatal cases. Methadone 176-185 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 116-122 28184434-9 2017 These results indicate that these three CYP2B6 SNPs are associated with methadone fatalities. Methadone 72-81 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 27709010-5 2016 CYP2B6 has been demonstrated to play a role in the metabolism of 2%-10% of clinically used drugs including widely used antineoplastic agents cyclophosphamide and ifosfamide, anesthetics propofol and ketamine, synthetic opioids pethidine and methadone, and the antiretrovirals nevirapine and efavirenz, among others. Methadone 241-250 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 28263461-8 2017 However, CYP2B6 is also a major catalyst of methadone metabolism in vitro. Methadone 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 28263461-9 2017 It has now been unequivocally established that CYP2B6, not CYP3A4, is the principal determinant of methadone metabolism, clearance, elimination, and plasma concentrations in humans. Methadone 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 28263461-11 2017 CYP2B6 genetics also influences methadone metabolism and clearance, which were diminished in CYP2B6*6 carriers and increased in CYP2B6*4 carriers. Methadone 32-41 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 28263461-11 2017 CYP2B6 genetics also influences methadone metabolism and clearance, which were diminished in CYP2B6*6 carriers and increased in CYP2B6*4 carriers. Methadone 32-41 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-99 28263461-11 2017 CYP2B6 genetics also influences methadone metabolism and clearance, which were diminished in CYP2B6*6 carriers and increased in CYP2B6*4 carriers. Methadone 32-41 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-99 28263461-12 2017 CYP2B6 genetics can explain, in part, interindividual variability in methadone metabolism and clearance. Methadone 69-78 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 28263461-13 2017 Thus, both constitutive variability due to CYP2B6 genetics, and CYP2B6-mediated drug interactions, can alter methadone disposition, clinical effect, and drug safety. Methadone 109-118 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 43-49 28263461-13 2017 Thus, both constitutive variability due to CYP2B6 genetics, and CYP2B6-mediated drug interactions, can alter methadone disposition, clinical effect, and drug safety. Methadone 109-118 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 64-70 27286724-8 2016 (S)-methadone clearance was influenced by cytochrome P450 (CYP) 2B6 activity, ABCB1 3435C>T, and alpha-1 acid glycoprotein level, while (R)-methadone clearance was influenced by CYP2B6 activity, POR*28, and CYP3A4*22. Methadone 0-13 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 42-67 27286724-8 2016 (S)-methadone clearance was influenced by cytochrome P450 (CYP) 2B6 activity, ABCB1 3435C>T, and alpha-1 acid glycoprotein level, while (R)-methadone clearance was influenced by CYP2B6 activity, POR*28, and CYP3A4*22. Methadone 0-13 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 181-187 25456329-8 2014 The presence of the rs3745274 minor allele (CYP2B6 515G>T) reduced CL/F by up to 20% for S-methadone only. Methadone 92-103 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 44-50 27289271-0 2016 Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). Methadone 96-105 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 27289271-1 2016 BACKGROUND: CYP2B6 polymorphisms contribute to inter-individual variations in pharmacokinetics of methadone. Methadone 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 27289271-3 2016 It is possible, therefore, that genetic polymorphisms in CYP2B6, which affects the metabolism of methadone, influence pain sensitivity among patients on MMT. Methadone 97-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 27515451-0 2016 CYP2B6 and OPRM1 Receptor Polymorphisms at Methadone Clinics And Novel OPRM1 Haplotypes: A Cross-Sectional Study. Methadone 43-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 27515451-3 2016 OBJECTIVE: This study sought to detect CYP2B6 and OPRM1 variants and their genotypes, as major contributors to inter-variability in methadone responsiveness and methadone dose requirements. Methadone 132-141 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 27515451-3 2016 OBJECTIVE: This study sought to detect CYP2B6 and OPRM1 variants and their genotypes, as major contributors to inter-variability in methadone responsiveness and methadone dose requirements. Methadone 161-170 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 26389554-0 2015 Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 26389554-2 2015 Cytochrome P4502B6 (CYP2B6) is the principle determinant of clinical methadone elimination. Methadone 69-78 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 26389554-4 2015 CYP2B6.6, the protein encoded by the CYP2B6*6 polymorphism, deficiently catalyzes methadone metabolism in vitro. Methadone 82-91 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26389554-4 2015 CYP2B6.6, the protein encoded by the CYP2B6*6 polymorphism, deficiently catalyzes methadone metabolism in vitro. Methadone 82-91 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 26389554-5 2015 This investigation determined the influence of CYP2B6*6, and other allelic variants encountered, on methadone concentrations, clearance, and metabolism. Methadone 100-109 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 26389554-8 2015 RESULTS: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. Methadone 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 77-83 26389554-8 2015 RESULTS: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. Methadone 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-99 26389554-8 2015 RESULTS: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. Methadone 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-99 26389554-9 2015 R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. Methadone 0-11 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 60-66 26389554-9 2015 R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. Methadone 0-11 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 76-82 26389554-9 2015 R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. Methadone 0-11 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 76-82 26389554-12 2015 Methadone metabolism and clearance were lower in African Americans in part because of the CYP2B6*6 genetic polymorphism. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-96 26389554-13 2015 CONCLUSIONS: CYP2B6 polymorphisms influence methadone plasma concentrations, because of altered methadone metabolism and thus clearance. Methadone 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 26389554-13 2015 CONCLUSIONS: CYP2B6 polymorphisms influence methadone plasma concentrations, because of altered methadone metabolism and thus clearance. Methadone 96-105 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 26389554-15 2015 CYP2B6 pharmacogenetics explains, in part, interindividual variability in methadone elimination. Methadone 74-83 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26389554-16 2015 CYP2B6 genetic effects on methadone metabolism and clearance may identify subjects at risk for methadone toxicity and drug interactions. Methadone 26-35 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26389554-16 2015 CYP2B6 genetic effects on methadone metabolism and clearance may identify subjects at risk for methadone toxicity and drug interactions. Methadone 95-104 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 25897175-0 2015 Differences in Methadone Metabolism by CYP2B6 Variants. Methadone 15-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 25897175-2 2015 Cytochrome P450 2B6 (CYP2B6) mediates clinical methadone clearance and metabolic inactivation via N-demethylation to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). Methadone 47-56 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-19 25897175-2 2015 Cytochrome P450 2B6 (CYP2B6) mediates clinical methadone clearance and metabolic inactivation via N-demethylation to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). Methadone 47-56 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 25897175-3 2015 Retrospective studies suggest that individuals with the CYP2B6*6 allelic variant have higher methadone plasma concentrations. Methadone 93-102 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 25897175-5 2015 This investigation evaluated methadone N-demethylation by expressed human CYP2B6 allelic variants in an insect cell coexpression system containing P450 reductase. Methadone 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 25897175-7 2015 EDDP formation from therapeutic (0.25-1 muM) R- and S-methadone concentrations was CYP2B6.4 >= CYP2B6.1 >= CYP2B6.5 >> CYP2B6.9 CYP2B6.6, and undetectable from CYP2B6.18. Methadone 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 83-89 25897175-7 2015 EDDP formation from therapeutic (0.25-1 muM) R- and S-methadone concentrations was CYP2B6.4 >= CYP2B6.1 >= CYP2B6.5 >> CYP2B6.9 CYP2B6.6, and undetectable from CYP2B6.18. Methadone 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 25897175-7 2015 EDDP formation from therapeutic (0.25-1 muM) R- and S-methadone concentrations was CYP2B6.4 >= CYP2B6.1 >= CYP2B6.5 >> CYP2B6.9 CYP2B6.6, and undetectable from CYP2B6.18. Methadone 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 25897175-7 2015 EDDP formation from therapeutic (0.25-1 muM) R- and S-methadone concentrations was CYP2B6.4 >= CYP2B6.1 >= CYP2B6.5 >> CYP2B6.9 CYP2B6.6, and undetectable from CYP2B6.18. Methadone 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 25897175-7 2015 EDDP formation from therapeutic (0.25-1 muM) R- and S-methadone concentrations was CYP2B6.4 >= CYP2B6.1 >= CYP2B6.5 >> CYP2B6.9 CYP2B6.6, and undetectable from CYP2B6.18. Methadone 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 25897175-7 2015 EDDP formation from therapeutic (0.25-1 muM) R- and S-methadone concentrations was CYP2B6.4 >= CYP2B6.1 >= CYP2B6.5 >> CYP2B6.9 CYP2B6.6, and undetectable from CYP2B6.18. Methadone 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 25897175-10 2015 Stereoselective methadone metabolism (S>R) was maintained with all CYP2B6 variants. Methadone 16-25 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 70-76 25897175-11 2015 These results show that methadone N-demethylation by CYP2B6.4 is greater compared with CYP2B6.1, whereas CYP2B6.9 and CYP2B6.6 (which both contain the 516G>T, Q172H polymorphism), are catalytically deficient. Methadone 24-33 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 53-59 25897175-13 2015 Differences in methadone metabolism by CYP2B6 allelic variants provide a mechanistic understanding of pharmacogenetic variability in clinical methadone metabolism and clearance. Methadone 15-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 25897175-13 2015 Differences in methadone metabolism by CYP2B6 allelic variants provide a mechanistic understanding of pharmacogenetic variability in clinical methadone metabolism and clearance. Methadone 142-151 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 26227254-6 2015 CYP2B6 pharmacogenetic testing of methadone may reduce the risk of cardiac toxicity associated with the S-enantiomer. Methadone 34-43 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 27010727-0 2016 Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. Methadone 37-46 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 27010727-0 2016 Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. Methadone 188-197 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 27010727-10 2016 The association between the S-methadone plasma concentration and CYP2B6, SPON1, and GSG1L were replicated in another independent study. Methadone 28-39 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 65-71 25801005-3 2015 Methadone is N-demethylated to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) by CYP2B6 and CYP3A4 in vitro, but by CYP2B6 in vivo. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 91-97 25801005-3 2015 Methadone is N-demethylated to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) by CYP2B6 and CYP3A4 in vitro, but by CYP2B6 in vivo. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 126-132 23834474-5 2014 For verification, the pregnancy-related changes in the disposition of methadone (cleared by CYP2B6, 3A and 2C19) and glyburide (cleared by CYP3A, 2C9 and 2C19) were predicted. Methadone 70-79 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 92-98 24489693-0 2014 Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. Methadone 52-61 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 24489693-2 2014 OBJECTIVES: To determine whether the CYP2B6*6 or ABCB1 (rs1045642) polymorphisms are associated with variation in methadone response (plasma concentration, dose, or response to treatment). Methadone 114-123 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 25278738-5 2013 Genes encoding the liver cytochrome P-450 (CYP) enzymes that are involved with the metabolism of methadone (CYP2B6, 3A4 and 2C19) were selected and genotyped in this cohort. Methadone 97-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 108-114 25278738-6 2013 We found that the SNPs on CYP2B6 were associated with plasma S-methadone concentration; SNPs on CYP3A4 were associated with withdrawal symptoms and side effects; and SNPs on CYP2C19 were associated with methadone dose. Methadone 63-72 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-32 25278738-6 2013 We found that the SNPs on CYP2B6 were associated with plasma S-methadone concentration; SNPs on CYP3A4 were associated with withdrawal symptoms and side effects; and SNPs on CYP2C19 were associated with methadone dose. Methadone 203-212 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-32 24489693-4 2014 We included studies that reported methadone plasma concentration, methadone response, or methadone dose in relation to the CYP2B6*6 or ABCB1 polymorphisms. Methadone 34-43 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 123-129 24489693-7 2014 Trough (R) methadone plasma concentration was significantly higher in CYP2B6*6 homozygous carriers when compared to non-carriers (standardized mean difference [SMD] = 0.53, 95% confidence interval [CI], 0.05-1.00, p = 0.03) with minimal heterogeneity (I(2) = 0%). Methadone 11-20 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 70-76 24489693-11 2014 CONCLUSION: Although the number of studies included and sample size were modest, this is the first meta analysis to show participants homozygous for the CYP2B6*6 genotype have higher trough (R) and (S) methadone plasma concentrations, suggesting that methadone metabolism is significantly slower in *6 homozygous carriers. Methadone 202-211 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 153-159 24489693-11 2014 CONCLUSION: Although the number of studies included and sample size were modest, this is the first meta analysis to show participants homozygous for the CYP2B6*6 genotype have higher trough (R) and (S) methadone plasma concentrations, suggesting that methadone metabolism is significantly slower in *6 homozygous carriers. Methadone 251-260 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 153-159 23733841-9 2013 RESULTS: Methadone (10 microM) increased methadone N-demethylation 2-fold, CYP2B6 and CYP3A4 mRNA 3-fold, and protein expression 2-fold. Methadone 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 75-81 21790905-0 2013 CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Methadone 32-41 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 21790905-3 2013 Methadone metabolism is attributed primarily to cytochrome P450 enzymes CYP3A4, CYP2B6 and CYP2D6. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 80-86 21790905-4 2013 The CYP2B6*6 allele [single nucleotide polymorphisms (SNPs) 785A>G (rs2279343) and 516G>T (rs3745274)] was associated with slow methadone metabolism. Methadone 134-143 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 21790905-5 2013 To explore the effects of CYP2B6*6 allele on methadone dose requirement, it was genotyped in a well-characterized sample of 74 Israeli former heroin addicts in MMT. Methadone 45-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-32 21790905-9 2013 The mean methadone doses required by subjects homozygous for the variant alleles of the CYP2B6 SNPs 785A>G and 516G>T (88, 96mg, respectively) were significantly lower than those of the heterozygotes (133, 129mg, respectively) and the non-carriers (150, 151mg, respectively) (nominal P=0.012, 0.048, respectively). Methadone 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 88-94 23733841-3 2013 Although methadone N-demethylation is catalyzed in vitro by cytochrome P4502B6 (CYP2B6) and CYP3A4, and clearance in vivo depends on CYP2B6, mechanism(s) of autoinduction are incompletely understood. Methadone 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 80-86 23733841-3 2013 Although methadone N-demethylation is catalyzed in vitro by cytochrome P4502B6 (CYP2B6) and CYP3A4, and clearance in vivo depends on CYP2B6, mechanism(s) of autoinduction are incompletely understood. Methadone 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-139 23733841-16 2013 CONCLUSIONS: Methadone caused concentration-dependent autoinduction of methadone N-demethylation in human hepatocytes, related to induction of CYP2B6 and CYP3A4 mRNA expression, protein expression, and catalytic activity. Methadone 13-22 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 143-149 23361846-0 2013 Role of cytochrome P4502B6 in methadone metabolism and clearance. Methadone 30-39 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-26 23298862-0 2013 Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 23298862-0 2013 Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 23298862-2 2013 Methadone metabolism clinically occurs primarily by N-demethylation to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), catalyzed predominantly by CYP2B6. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 151-157 23298862-3 2013 Retrospective studies suggest that the common allele variant CYP2B6*6 may influence methadone plasma concentrations. Methadone 84-93 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 61-67 23298862-5 2013 This investigation compared methadone N-demethylation by CYP2B6.6 with that by wild-type CYP2B6.1. Methadone 28-37 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 23298862-6 2013 Methadone enantiomer and racemate N-demethylation by recombinant-expressed CYP2B6.6 and CYP2B6.1 was determined. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 75-81 23298862-6 2013 Methadone enantiomer and racemate N-demethylation by recombinant-expressed CYP2B6.6 and CYP2B6.1 was determined. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 88-94 23298862-7 2013 At substrate concentrations (0.25-2 microM) approximating plasma concentrations occurring clinically, rates of methadone enantiomer N-demethylation by CYP2B6.6, incubated individually or as the racemate, were one-third to one-fourth those by CYP2B6.1. Methadone 111-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 151-157 23298862-7 2013 At substrate concentrations (0.25-2 microM) approximating plasma concentrations occurring clinically, rates of methadone enantiomer N-demethylation by CYP2B6.6, incubated individually or as the racemate, were one-third to one-fourth those by CYP2B6.1. Methadone 111-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 242-248 23298862-8 2013 For methadone individual enantiomers and metabolism by CYP2B6.6 compared with CYP2B6.1, Vmax was diminished, Ks was greater and the in vitro intrinsic clearance was diminished 5- to 6-fold. Methadone 4-13 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 55-61 23298862-8 2013 For methadone individual enantiomers and metabolism by CYP2B6.6 compared with CYP2B6.1, Vmax was diminished, Ks was greater and the in vitro intrinsic clearance was diminished 5- to 6-fold. Methadone 4-13 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 23298862-10 2013 Both CYP2B6.6 and CYP2B6.1 showed similar stereoselectivity (S>R-methadone). Methadone 66-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 5-11 23298862-10 2013 Both CYP2B6.6 and CYP2B6.1 showed similar stereoselectivity (S>R-methadone). Methadone 66-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-24 23298862-11 2013 Human liver microsomes with diminished CYP2B6 content due to a CYP2B6*6 allele had lower rates of methadone N-demethylation. Methadone 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 23298862-11 2013 Human liver microsomes with diminished CYP2B6 content due to a CYP2B6*6 allele had lower rates of methadone N-demethylation. Methadone 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 23298862-12 2013 Results show that methadone N-demethylation catalyzed by CYP2B6.6, the CYP2B6 variant encoded by the CYP2B6*6 polymorphism, is catalytically deficient compared with wild-type CYP2B6.1. Methadone 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 23298862-12 2013 Results show that methadone N-demethylation catalyzed by CYP2B6.6, the CYP2B6 variant encoded by the CYP2B6*6 polymorphism, is catalytically deficient compared with wild-type CYP2B6.1. Methadone 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 71-77 23298862-12 2013 Results show that methadone N-demethylation catalyzed by CYP2B6.6, the CYP2B6 variant encoded by the CYP2B6*6 polymorphism, is catalytically deficient compared with wild-type CYP2B6.1. Methadone 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 71-77 23298862-12 2013 Results show that methadone N-demethylation catalyzed by CYP2B6.6, the CYP2B6 variant encoded by the CYP2B6*6 polymorphism, is catalytically deficient compared with wild-type CYP2B6.1. Methadone 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 71-77 23298862-13 2013 Diminished methadone N-demethylation by CYP2B6.6 may provide a mechanistic explanation for clinical observations of altered methadone disposition in individuals carrying the CYP2B6*6 polymorphism. Methadone 11-20 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 23298862-13 2013 Diminished methadone N-demethylation by CYP2B6.6 may provide a mechanistic explanation for clinical observations of altered methadone disposition in individuals carrying the CYP2B6*6 polymorphism. Methadone 11-20 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 174-180 23298862-13 2013 Diminished methadone N-demethylation by CYP2B6.6 may provide a mechanistic explanation for clinical observations of altered methadone disposition in individuals carrying the CYP2B6*6 polymorphism. Methadone 124-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 23298862-13 2013 Diminished methadone N-demethylation by CYP2B6.6 may provide a mechanistic explanation for clinical observations of altered methadone disposition in individuals carrying the CYP2B6*6 polymorphism. Methadone 124-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 174-180 23467454-3 2013 Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. Methadone 110-119 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 23361846-1 2013 Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 59-77 23361846-1 2013 Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 79-85 23361846-2 2013 This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days. Methadone 105-114 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 46-52 23361846-7 2013 CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition. Methadone 26-35 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 23361846-7 2013 CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition. Methadone 78-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 23361846-7 2013 CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition. Methadone 78-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 140-146 23361846-7 2013 CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition. Methadone 78-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 23361846-7 2013 CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition. Methadone 78-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 140-146 23288240-0 2013 PXR polymorphisms interacted with CYP2B6 polymorphisms on methadone metabolites. Methadone 58-67 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 22815312-0 2013 Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Methadone 111-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 23249875-0 2013 Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Methadone 53-66 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 23249875-1 2013 BACKGROUND: (S)-Methadone, metabolized mainly by CYP2B6, shows a wide interindividual variability in its pharmacokinetics and pharmacodynamics. Methadone 12-25 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 49-55 23249875-2 2013 METHODS: Resequencing of the CYP2B6 gene was performed in 12 and 35 selected individuals with high (S)-methadone plasma exposure and low (S)-methadone plasma exposure, respectively, from a previously described cohort of 276 patients undergoing methadone maintenance treatment. Methadone 103-112 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-35 23249875-2 2013 METHODS: Resequencing of the CYP2B6 gene was performed in 12 and 35 selected individuals with high (S)-methadone plasma exposure and low (S)-methadone plasma exposure, respectively, from a previously described cohort of 276 patients undergoing methadone maintenance treatment. Methadone 141-150 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-35 23249875-2 2013 METHODS: Resequencing of the CYP2B6 gene was performed in 12 and 35 selected individuals with high (S)-methadone plasma exposure and low (S)-methadone plasma exposure, respectively, from a previously described cohort of 276 patients undergoing methadone maintenance treatment. Methadone 141-150 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-35 23249875-8 2013 CONCLUSION: Known genetic polymorphisms in CYP2B6 contribute toward explaining extreme (S)-methadone plasma levels observed in a cohort of patients following methadone maintenance treatment. Methadone 87-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 43-49 23249875-8 2013 CONCLUSION: Known genetic polymorphisms in CYP2B6 contribute toward explaining extreme (S)-methadone plasma levels observed in a cohort of patients following methadone maintenance treatment. Methadone 91-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 43-49 23298916-2 2012 Their multiethnic populations suggest complexity due to the genetic polymorphism, such as CYP2B6 that metabolizes methadone and anti-retroviral. Methadone 114-123 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-96 24455721-3 2013 The results demonstrated that the methadone maintenance dose, CYP2B6 785G allele, and ABCB1 2677T allele have positive effects on the methadone plasma concentration. Methadone 134-143 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 62-68 22926004-9 2013 Women with the CYP2B6 Q172 variant GT genotype have consistently higher L/D values for S-methadone across both pregnancy and postpartum. Methadone 87-98 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 22398970-10 2012 Methadone disposition was most consistent with efavirenz induction of hepatic CYP2B6-mediated methadone N-demethylation. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 22685215-0 2012 Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme. Methadone 55-64 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-51 22685215-4 2012 However, recent clinical data have indicated that CYP2B6 is actually the major isoform responsible for methadone metabolism and clearance in vivo. Methadone 103-112 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 50-56 22685215-5 2012 In this study, methadone was shown to act as a mechanism-based inactivator of CYP2B6. Methadone 15-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 22685215-6 2012 Methadone inactivates CYP2B6 in a time-, concentration-, and NADPH-dependent manner with a K(I) = 10.0 muM and k(inact) = 0.027 min-1. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 22-28 22685215-7 2012 The loss of CYP2B6 activity in the presence of methadone and NADPH occurred with concomitant loss of the reduced CO spectrum of the P450. Methadone 47-56 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 22685215-11 2012 The evidence strongly suggests that destruction of prosthetic heme is the underlying mechanism leading to the inactivation of CYP2B6 by methadone. Methadone 136-145 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 126-132 22511698-2 2012 Methadone is primarily metabolized by N-demethylation to an inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) by CYP3A4 and CYP2B6. Methadone 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 151-157 22722506-3 2012 The complete metabolic disposition of methadone is likely to involve a number of enzymes, including specifically CYP2B6. Methadone 38-47 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 113-119 22398970-10 2012 Methadone disposition was most consistent with efavirenz induction of hepatic CYP2B6-mediated methadone N-demethylation. Methadone 94-103 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 20668445-8 2010 The risk of a methadone-related fatality during treatment may be evaluated in part by screening for CYP2B6*6 and A118G. Methadone 14-23 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 100-106 21902500-3 2011 RESULTS: Pair-wise comparisons revealed that carriers of the variants ABCB1 3435C>T or CYP2B6 516G>T alleles were more likely to require a higher methadone dose than noncarriers (both p < 0.0001). Methadone 152-161 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-96 21902500-5 2011 Proportional odds regression with adjustment of cofactors demonstrated that ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genetic variants were jointly correlated with optimal methadone dose (adjusted r(2) = 53%). Methadone 167-176 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 83-89 21902501-2 2011 The isozyme CYP3A4 of the CYP system is one of the metabolic enzymes, as well as CYP2B6, responsible for the metabolism of methadone. Methadone 123-132 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-87 21158011-0 2011 CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Methadone 41-50 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 21158011-3 2011 A significant association between high methadone concentrations and the CYP2B6*6 allele characteristic of the slow metabolizer phenotype was identified. Methadone 39-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 21158011-4 2011 We suggest that the risk of methadone fatality may be predetermined in part by the CYP2B6*6 allele. Methadone 28-37 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 83-89 20668445-0 2010 OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Methadone 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 10-16 20668445-2 2010 We have examined the association between CYP2B6 and micro-opioid receptor (OPRM1) gene variations and apparent susceptibility to methadone poisoning. Methadone 129-138 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 41-47 20668445-5 2010 CYP2B6 *4, *9, and *6 alleles were found to be associated with higher postmortem methadone concentrations in blood (P < or = 0.05). Methadone 81-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 21871151-7 2011 Individual susceptibility to methadone may be determined by screening for CYP2B6*6. Methadone 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 21694616-0 2011 CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. Methadone 77-86 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 21694616-10 2011 We conclude that genetic polymorphisms in the CYP2B6 gene may therefore be indicators of the clearance, plasma concentration and C/D ratio of S-methadone. Methadone 142-153 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 46-52 19904716-2 2010 This method was established by the characteristics of recombinant cytochrome P-450 (CYP) isozymes, where CYP2C19 prefers to metabolize R-methadone and CYP2B6 prefers to metabolize S-methadone. Methadone 180-191 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 151-157 22190985-5 2009 The pronounced inhibitory impact of voriconazole on methadone metabolism via the cytochrome P450 (CYP)2B6 isoenzyme was identified as a probable cause of the arrhythmia. Methadone 52-61 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-105 18781911-5 2008 These individual differences may result in variable systemic exposure to drugs metabolized by CYP2B6, including the antineoplastics cyclophosphamide and ifosfamide, the antiretrovirals nevirapine and efavirenz, the anesthetics propofol and ketamine, the synthetic opioid methadone, and the anti-Parkinsonian selegiline. Methadone 271-280 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 94-100 19356104-4 2008 Therefore, the methadone-maintenance-treatment outcome should be evaluated when patients are treated with drugs which are supposed to induce CYP3A4 and CYP2B6 isoforms. Methadone 15-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 152-158 18292673-0 2008 Role of CYP2B6 in stereoselective human methadone metabolism. Methadone 40-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-14 18292673-15 2008 CONCLUSIONS: These results suggest a significant role for CYP2B6, but not CYP3A, in stereoselective human methadone metabolism and disposition. Methadone 106-115 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 58-64 18292673-4 2008 Nevertheless, recent clinical data do not support a primary role for CYP3A4 and suggest that CYP2B6 may mediate methadone clearance. Methadone 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-99 18292673-7 2008 METHODS: N-demethylation of racemic methadone and individual enantiomers by expressed CYPs 2B6, 2C19, and 3A4 was evaluated. Methadone 36-45 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 86-100 18292673-10 2008 RESULTS: At clinical concentrations, methadone enantiomer N-demethylation by recombinant CYPs 2B6, 3A4, and 2C19 was S > R, S = R, and S << R. Greater stereoselective metabolism (S > R) occurred in livers expressing high levels of CYP2B6 compared with CYP3A4. Methadone 37-46 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 243-249 17329992-4 2007 As CYP2B6 slow metabolizer (SM) status results in a reduced ability to metabolize (S)-methadone, electrocardiograms, CYP2B6 genotypes, and (R)- and (S)-methadone plasma concentrations were obtained for 179 patients receiving (R,S)-methadone. Methadone 82-95 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 3-9 17598095-2 2007 METHODS: Methadone was incubated with various drugs (n = 10) and cDNA-expressed CYP3A4, CYP2D6, CYP2B6, CYP2C19 and CYP1A2 enzymes to screen for their inhibition potency. Methadone 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 96-102 17329992-4 2007 As CYP2B6 slow metabolizer (SM) status results in a reduced ability to metabolize (S)-methadone, electrocardiograms, CYP2B6 genotypes, and (R)- and (S)-methadone plasma concentrations were obtained for 179 patients receiving (R,S)-methadone. Methadone 148-161 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 3-9 17178267-6 2006 As previously reported, CYP2B6*6/*6 carriers had significantly higher trough (S)-methadone plasma levels (P = .0001) and a trend toward higher (R)-methadone plasma levels (P = .07). Methadone 77-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 17259447-3 2007 N-Demethylation of methadone in vitro is predominantly mediated by cytochrome P450 CYP3A4 and CYP2B6 and somewhat by CYP2C19. Methadone 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 94-100 17259447-4 2007 This investigation evaluated stereoselectivity, models, and kinetic parameters for methadone N-demethylation by recombinant CYP2B6, CYP3A4, and CYP2C19, and the potential for interactions between enantiomers during racemate metabolism. Methadone 83-92 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 124-130 17259447-9 2007 For CYP2B6, the interaction between enantiomers was stereoselective, with S-methadone as a more potent inhibitor of R-methadone N-demethylation than R-of S-methadone. Methadone 74-85 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 17259447-9 2007 For CYP2B6, the interaction between enantiomers was stereoselective, with S-methadone as a more potent inhibitor of R-methadone N-demethylation than R-of S-methadone. Methadone 116-127 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 17259447-9 2007 For CYP2B6, the interaction between enantiomers was stereoselective, with S-methadone as a more potent inhibitor of R-methadone N-demethylation than R-of S-methadone. Methadone 154-165 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 17259447-13 2007 Changes in plasma R/S methadone ratios observed after rifampin or troleandomycin pretreatment in humans in vivo were successfully predicted by CYP2B6- but not CYP3A4-catalyzed methadone N-demethylation. Methadone 22-31 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 143-149 17259447-14 2007 CYP2B6 is a predominant catalyst of stereoselective methadone metabolism in vitro. Methadone 52-61 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 17259447-15 2007 In vivo, CYP2B6 may be a major determinant of methadone metabolism and disposition, and CYP2B6 activity and stereoselective metabolic interactions may confer variability in methadone disposition. Methadone 46-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 17259447-15 2007 In vivo, CYP2B6 may be a major determinant of methadone metabolism and disposition, and CYP2B6 activity and stereoselective metabolic interactions may confer variability in methadone disposition. Methadone 173-182 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 88-94 17178267-6 2006 As previously reported, CYP2B6*6/*6 carriers had significantly higher trough (S)-methadone plasma levels (P = .0001) and a trend toward higher (R)-methadone plasma levels (P = .07). Methadone 143-156 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 17178267-12 2006 CONCLUSION: In vivo, CYP3A4 and CYP2B6 are the major CYP isoforms involved in methadone metabolism, with CYP2D6 contributing to a minor extent. Methadone 78-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-38 16338275-1 2005 BACKGROUND AND OBJECTIVE: Recent in vitro studies have suggested an important role of cytochrome P450 (CYP) 2B6 and CYP2C19 in methadone metabolism. Methadone 127-136 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 86-111 16338275-2 2005 We aimed to determine the influence of CYP2B6, CYP2C9, and CYP2C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment. Methadone 91-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 16338275-6 2005 RESULTS: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . Methadone 36-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 16338275-6 2005 RESULTS: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . Methadone 75-88 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 16338275-6 2005 RESULTS: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . Methadone 40-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 16338275-13 2005 CONCLUSION: Although CYP2B6 influences (S)-methadone plasma levels, given that only (R)-methadone contributes to the opioid effect of this drug, a major influence of CYP2B6 genotype on response to treatment is unlikely and has not been shown in this study. Methadone 39-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27